Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.

Tokyo Tokyo (tō`kēō), city (1990 pop. 8,163,573), capital of Japan and of Tokyo prefecture, E central Honshu, at the head of Tokyo Bay. , Japan, July July: see month. 4, 2006 - (JCN JCN Japan Corporate News
JCN Journal of Cognitive Neuroscience
JCN Journal of Cardiovascular Nursing
JCN Journal of Christian Nursing
JCN Job Control Number
JCN Journal of Child Neurology
JCN joint communications network (US DoD) ) - Eisai Co., Ltd. has established a new pharmaceutical marketing subsidiary in Singapore, Eisai (Singapore) Pte., Ltd. (ESN (Electronic Serial Number) A unique identification number built into a cellphone for security purposes. ), which has launched pharmaceutical import and marketing business.

Previously, Eisai's pharmaceutical import and marketing business in Singapore was handled by Eisai Asia Regional Services Pte. Ltd. (EARS), but EARS has recently transferred this business to ESN.

By launching operations with this new company, Eisai aims to strengthen its pharmaceutical business in Singapore and further contribute to patient satisfaction in the region.

EARS will renew its operations as a holding company assuming specific responsibility for the seven local subsidiaries in the Asian region, including this newly established ESN in Singapore and six others existing subsidiaries in China, Thailand, Malaysia, the Philippines, Hong Kong Hong Kong (hŏng kŏng), Mandarin Xianggang, special administrative region of China, formerly a British crown colony (2005 est. pop. 6,899,000), land area 422 sq mi (1,092 sq km), adjacent to Guangdong prov. and India.

Profile of Eisai (Singapore) Pte. Ltd.

<pre>

Capital: 300,000 Singapore dollars (approx. 22,000,000 yen)

Location: Singapore

President: Celine Ting

Scope of Business: Import, marketing, and promotion of pharmaceuticals

Capital Alliance: 100% subsidiary of EARS

</pre>

Copyright [c] 2006 Japan Corporate News Network. All rights reserved.

COPYRIGHT 2006 Japan Corporate News Network K.K.
No portion of this article can be reproduced without the express written permission from the copyright holder.

Reader Opinion

Article Details
Printer friendly Cite/link Email Feedback
Publication:	JCNN News Summaries
Geographic Code:	9JAPA
Date:	Jul 6, 2006
Words:	175
Previous Article:	'K Line' Launches Coal Carrier for Electric Power Development Co. (J-Power).
Next Article:	Renesas Technology Expands Global Development and Design Capability.
Topics:	Pharmaceutical industry

Related Articles
Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan.
Eisai Establishes European Strategic Business Hub in the U.K.
Dainippon Sumitomo Pharma and Eisai Sign Licensing Agreement for "Gasmotin", a Gastroprokinetic Agent, for Countries in Asia including ASEAN Members.
A prescription for success: finding career opportunities in the pharmaceutical industry.
Eisai Pharmaceutical Marketing Subsidiary in Singapore Launches Operations.
Eisai Lawsuit Against Generic Drug Manufacturers Dismissed.
Eisai Recieves Positive Opinion for Inovelon(R) Marketing Authorization from European Committee for Medicinal Products for Human Use (CHMP).
Eisai Announces Inovelon(R) Receives Marketing Authorization Approval from European Commission.
Eisai Establishes New Manufacturing Subsidiary in United Kingdom.
A Once-weekly Formulation of Risedronate Sodium Hydrate, an Antiosteoporotic Agent, Was Approved.